

## Research Activities Newsletter

---

March 2023

### In the News: Congratulations to the following awardees!!



**Hailey Banack**, Research Assistant Professor of Epidemiology & Environmental Health (EEH), is PI on a continuation award from The National Cancer Institute/NIH for the project entitled, *Ms. LILAC: Muscle Mass in the Life and Longevity After Cancer (LILAC) Study*. The study's results will contribute to the development of public health recommendations and intervention strategies to prevent low muscle mass and associated adverse health outcomes in older and long-term cancer survivors. Co-Investigators from EEH include **Jean Wactawski-Wende**, Dean of SPHP and SUNY Distinguished Professor, and **Heather Ochs-Balcom**, Associate Professor.



**Saptarshi Chakraborty**, Assistant Professor of Biostatistics, is Co-I on a continuation award from the National Institute of Biomedical Imaging and Bioengineering/NIH (PI: Jun Xia, Biomedical Engineering) for the project entitled *Development of Photoacoustic Tomography for Non-invasive, Label-free Imaging of Tissue Perfusion in Chronic Wounds*. This project aims to develop a three-dimensional wound assessment system using photoacoustic tomography, a hybrid modality that detects optical absorption in tissue through the photoacoustic effect.



**Rachel Hageman Blair**, Associate Professor of Biostatistics, is PI on a new award from Jackson Laboratory/NIH for the project entitled, *Genetic Variation in Opiate Induced Respiratory Depression in Mice*. The project's long-term goal is to define the biological basis of opioid overdose risk and to discover safe and effective novel reversal agents. The overall objective of this proposal is to define the molecular mechanisms underlying individual variability in respiratory responses to opioids that indicate specific sensitivities to opioids and pharmacological alternatives to naloxone.



**Jessica Kruger**, Clinical Associate Professor of Community Health and Health Behavior, is Co-I on a new award from the Association of American Medical Colleges (PI: Alison Vargovich, Medicine) for the project entitled, *AAMC Improving Clinical and Public Health Outcomes through National Partnerships to Prevent and Control Emerging and Re-Emerging Infections Disease Threats*. A previous pilot program showed improvement in student self-efficacy in addressing medical misinformation and vaccine hesitancy. This award will allow the results from the pilot program to be expanded to students in other health professions and become publicly available.



**Jessica Kulak**, Clinical Assistant Professor of Community Health and Health Behavior (CHHB), is MPI on a new award from NYS Office of Addiction Services and Supports (OASAS) for the project entitled, *New York Statewide Young Adult Survey*. The project consists of a prevalence survey of substance use and related risk and resilience factors, for non-institutionalized adults, ages 19 through 25 years of age in New York State. The survey data collected will provide data for addressing key issues on risk and resilience factors related to substance use; data and findings will be returned to OASAS. **Gregory Homish**, Professor and Chair of CHHB, and **Gregory Wilding**, Professor and Chair of Biostatistics, are Co-Investigators on the project.



**Lucia Leone**, Associate Professor, Department of Community Health and Health Behavior, is PI on a continuation award from the National Cancer Institute/NIH, for the project entitled, *Effectiveness and Implementation of a Research Tested Mobile Produce Market Designed to Improve Diet in Underserved Communities*. This study will continue to implement a mobile

produce market program with eight organizations nationwide to determine if the effect can be replicated. It also includes development of a best-practices toolkit to help others sustainably implement the program.

### ***In This Issue***

<b>In the News: Congratulations to the Following Awardees .....</b>	<b>1</b>
<b>Grant Clinic.....</b>	<b>2</b>
<b>NIH Funding Opportunities</b>	
<b>Request for Applications (RFA) .....</b>	<b>4</b>
<b>Program Announcements Reviews in an Institute (PAR) .....</b>	<b>9</b>
<b>Program Announcement (PA).....</b>	<b>12</b>
<b>Words to Live By .....</b>	<b>12</b>

## **Grant Clinic**

### **GENERAL NOTICE**

#### [NOT-NR-23-008](#)

##### **Request for Information (RFI): Future Directions in Violence Against Women Research**

This Request for Information (RFI) is intended to gather public input on priority scientific directions in violence against women (VAW) research. This includes cisgender, transgender, and gender-diverse persons who identify as a woman or girl, as well as other individuals assigned female at birth but who may not identify as a woman or girl. To ensure consideration, responses should be submitted via email to [NINRProgram@nih.gov](mailto:NINRProgram@nih.gov) no later than *March 31, 2023*. Please indicate “VAW RFI Response” in the subject line of the email.

#### [NOT-DA-23-018](#)

##### **Notice of Intent to Reissue PA-20-208, Substance Use/Substance Use Disorder Dissertation Research Award**

This Notice is to inform the research community that the National Institute on Drug Abuse (NIDA) intends to reissue the Notice of Funding Opportunity (NOFO) [PA-20-208](#). The NOFO is expected to be published in Spring 2023 with an expected application due date in Fall 2023 and will utilize the R36 activity code.

#### [NOT-HS-23-008](#)

##### **Notice of Intent to Publish Funding Opportunity Announcement to Implement and Evaluate New Models for Delivering Comprehensive, Coordinated, Person-Centered Care to People with Long COVID**

The Agency for Healthcare Research and Quality (AHRQ) intends to publish a new RFA to expand access to comprehensive, coordinated, and person-centered care for people with Long COVID, particularly underserved, rural, vulnerable, or minority populations that are disproportionately impacted by the effects of Long COVID. AHRQ anticipates publishing the RFA in April or May 2023 and making up to \$9,000,000 in awards by September 30, 2023.

[NOT-DA-23-017](#)

**Notice of Joint NSF/NIDA Initiative to Support Research in Incorporating Human Behavior into Epidemiological Models Program**

The purpose of this notice announces the participation of the NIDA, effective immediately, in a joint initiative, the Incorporating Human Behavior in Epidemiological Models (IHBEM) Program, in collaboration with the National Science Foundation (NSF). The IHBEM announcement is released under [NSF-23-546](#). The purpose of the IHBEM activity is to support interdisciplinary collaborations that integrate research on behavioral and/or social processes in mathematical epidemiological models.

[NOT-AA-23-005](#)

**Notice of Intent to Publish a Funding Opportunity Announcement for HIV Prevention and Alcohol (R01 Clinical Trial Optional)**

The NIAAA intends to promote a new initiative by publishing an FOA to solicit applications to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. The FOA is expected to be published in Spring 2023 with an expected application due date of June 5, 2023 and initial funding in Spring 2024.

[NOT-AA-23-006](#)

**Notice of Intent to Publish a Funding Opportunity Announcement for HIV Prevention and Alcohol (R34 Clinical Trials Optional)**

The FOA seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. This R34 Announcement supports studies that are both necessary and sufficient to inform the planning of a clinical trial within the scope of the companion announcement [[NOT-AA-23-005](#)].

## **NOTICE OF SPECIAL INTERESTS**

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-CA-23-037](#) – **Technology Development for Cancer Control and Population Science Research**

The purpose of this Notice is to encourage grant applications for the development of novel technologies to support the needs of cancer control and population sciences research including healthcare delivery research, surveillance research, behavioral research, cancer epidemiology, and population scale -omics research with the goal of driving innovation in this field. This Notice applies to due dates on or after **March 1, 2023**, and subsequent receipt dates through **December 31, 2024**.

[NOT-HD-23-003](#) – **Research to Improve Pre-Pregnancy Care and Enhance Healthy Birth Intervals**

The purpose of this NOSI is to encourage research on the processes that facilitate or hinder the achievement of healthy interbirth intervals and promote healthy birth outcomes. This NOSI invites research applications that assess the causal social and behavioral processes that facilitate or hinder the achievement of healthy interbirth intervals and to identify mechanisms that can be modified by public health interventions at the levels of the dyad, family, community, or other population aggregates. This Notice applies to due dates on or after **June 5, 2023**, and subsequent receipt dates through **May 8, 2024**.

[NOT-DA-24-001](#) – **Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A jump into Precision Medicine**

NIDA is interested in receiving research proposals focusing on studying pharmacogenomics in PLWH with SUD as a crucial step in the science of Precision Medicine, in the path of personalized care for HIV and drug abuse. This Notice applies to due dates on or after **June 5, 2023**, and subsequent receipt dates through **May 8, 2026**.

[NOT-MD-23-002](#) – **Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations**

The purpose of the immigrant health initiative is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations. This notice applies to due dates on or after **June 5, 2023**, and subsequent receipt dates through **June 8, 2026**.

[NOT-MD-23-003](#) – **Addressing Health Disparities Among Immigrant Populations Through Effective Interventions**

The purpose of the immigrant health initiative is to support research to design and implement effective interventions to enhance health advantages and reduce health disparities among U.S. immigrant populations (particularly agricultural workers, unaccompanied minors, first generation immigrants, and children of immigrant families) and address factors related to immigration experiences that affect health. Due dates are on or after **June 5, 2023**, and subsequent receipt dates through **June 8, 2026**.

[NOT-AA-23-003](#) – **Advancing mHealth Interventions for Understanding and Preventing Alcohol-Related Domestic Violence (DV)**

The purpose of this solicitation is to announce NIAAA's interest in addressing the critical need for research related to developing, testing, and intervening proximal to drinking occasions, when risk of DV is elevated, to decrease the likelihood of alcohol consumption at levels sufficient to trigger DV and to provide skills shown to reduce risk of DV perpetration and victimization. This notice applies to due dates on or after **June 5, 2023**, and subsequent receipt dates through **September 8, 2026**.

## NIH Funding Opportunities

### NIH Funding Opportunities: Request for Applications (RFA)

#### MAY 2023 DUE DATES

[RFA-ES-23-002](#) – (R24 Clinical Trial Not Allowed)

#### **Accelerating Data and Metadata Standards in the Environmental Health Sciences**

The purpose of this Funding Opportunity Announcement (FOA) is to support resource projects to enable Environmental Health Sciences (EHS) communities to openly develop, extend, adapt, or refine data and metadata standards as well as associated tools to implement standards. The initiative is intended to catalyze community-driven standards development and related implementation in environmental health. **Application Due Date:** May 10, 2023. **Expiration Date:** November 8, 2023.

#### JULY 2023 DUE DATES

[RFA-CA-23-025](#) – (U01 Clinical Trial Required)

#### **Addressing the Primary Care Needs of Cancer Survivors**

The purpose of this Funding Opportunity Announcement (FOA) is to support the development and testing of primary care practice (PCP)- and health system-level interventions and strategies to promote high quality care for adult cancer survivors during and/or after cancer treatment. The overall goal of this opportunity is to support high quality care for cancer survivors that integrates primary care from the point of diagnosis forward. **Application Due Date:** June 30, 2023. **Expiration Date:** July 1, 2023.

#### AUGUST 2023 DUE DATES

[RFA-DA-24-013](#) – (R01 Clinical Trials Not Allowed)

[RFA-DA-24-014](#) – (R21 Clinical Trials Not Allowed)

#### **Mechanisms and Targets at the Intersection of HIV and Substance Use**

The purpose of this FOA is to support research on the discovery and development of novel chemical and biological approaches to prevent and/or treat central nervous system (CNS) complications associated with HIV infection and substance use. *Letter of Intent due date – July 9, 2023.* **Application Due Date:** August 9, 2023.

[RFA-MD-23-004](#) – (R01 – Clinical Trial Optional)

**Community Level Interventions to Improve Minority Health and Reduce Health Disparities**

This opportunity will support research projects to develop and test prospective community-level interventions to improve minority health and decrease health disparities. The initiative will emphasize research priorities that can be addressed through community-engaged research approaches and that utilize the [NIMHD Research Framework](#) to assess and intervene on health determinants beyond the individual level, at the interpersonal, family, organizational, neighborhood, community, and societal levels. **Application Due Dates:** July 7, 2023; *AIDS* – August 9, 2023. **Expiration Date:** August 10, 2023.

[RFA-DA-24-008](#) – (R01 Clinical Trials Not Allowed)

[RFA-DA-24-009](#) – (R21 Clinical Trials Not Allowed)

**Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder**

The purpose of this FOA is to encourage research using data science and computational approaches to generate new insights into mechanisms and consequences of the interaction of HIV and addictive drugs. *Letter of Intent due date* – July 10, 2023. **Application Due Date:** August 10, 2023. **Expiration Date:** August 11, 2023.

**MULTIPLE DUE DATES**

[RFA-ES-23-007](#) (P20 Clinical Trial Optional)

**Exploratory Grants for Climate Change and Health Research Center Development**

The purpose of this NOFO is to solicit P20 planning grant applications for Climate Change and Health Research Centers (CCHRCs). This program will support the development of an innovative research environment to foster and sustain a transdisciplinary program of fundamental and applied research to explore the complex impacts of climate change on health and to develop action-oriented strategies that protect health and build resiliency at the individual, community, national and global levels. **Application Due Dates:** May 1, 2023 and November 7, 2023

[RFA-CA-22-050](#) (R01 Clinical Trial Optional)

**NCI Cancer Moonshot Scholars Diversity Program (CMSDP)**

The NCI, in alignment with NIH, continues to demonstrate a strong commitment to attracting, training, and retaining the best minds from diverse backgrounds to ensure long-term successes in the cancer research enterprise. The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups ([NOT-OD-20-031](#), Notice of NIH's Interest in Diversity), are encouraged to work with their institutions to apply. **Application Due Dates:** June 6, 2023 and February 6, 2024

[RFA-CA-23-014](#) – (R21 Clinical Trial Optional)

**Development of Innovation Informatics Methods and Algorithms for Cancer Research and Management**

The importance of this FOA is on supporting the development of novel informatics capabilities that involve a high degree of innovation and that have the potential to accelerate or enhance cancer research by inviting Exploratory/Developmental Research grant applications for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum. **Application Due Dates:** June 13, 2023 and November 17, 2023

[RFA-CA-23-015](#) – (U01 Clinical Trial Optional)

**Early-Stage Development of Informatics Technologies for Cancer Research and Management**

This FOA focuses on early-stage development, defined here as initial tool development or the significant modification of an existing tool for a new cancer research application. The FOA encourages applications that involve the development of new, user-friendly informatics technologies that support a wide range of cancer research, including discovery biology, population studies, as well as clinical and translational research. **Application Due Dates:** June 13, 2023 and November 17, 2023

[RFA-CA-23-016](#) – (U24 Clinical Trial Optional)

**Advanced Development of Informatics Technologies for Cancer Research and Management**

This FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. **Application Due Dates:** June 13, 2023 and November 17, 2023

[RFA-CA-23-017](#) – (U24 Clinical Trial Optional)

#### **Sustained Support for Informatics Technologies for Cancer Research and Management**

The purpose of this Announcement is to invite Cooperative Agreement applications for the continued development and sustainment of high-value informatics research resources to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. **Application Due Dates:** June 13, 2023 and November 17, 2023

[RFA-HL-23-018](#) (R21)

#### **Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research**

This mechanism supports research relevant to the NHLBI mission ([Strategic Vision | NHLBI, NIH](#)) using the existing biospecimen collections that are stored in the Biorepository. Descriptions and access to the available biospecimen collections and associated datasets can be found at the NHLBI Biospecimen and Data Repository Information Coordinating Center (BioLINCC) website at [www.biolincc.nhlbi.nih.gov](http://www.biolincc.nhlbi.nih.gov).

**Application Due Dates:** June 20, 2023; October 19, 2023; June 20, 2024; and October 21, 2024

[RFA-OD-23-013](#) – (R21 Clinical Trial Optional)

[RFA-OD-23-014](#) – (R01 Clinical Trial Optional)

#### **Understanding Chronic Conditions Understudied Among Women**

The purpose of this Funding Opportunity is to invite R21 applications on chronic conditions understudied among women and/or that disproportionately affect populations of women who are understudied, underrepresented, and underreported in biomedical Research should align with Goal 1 of the [2019-2023 Trans-NIH Strategic Plan for Women's Health Research](#) "Advancing Science for the Health of Women." **Application Due Dates:** June 20, 2023 and June 20, 2024

[RFA-DA-24-037](#) (R21 Clinical Trial Optional)

#### **Accelerating the Pace of Drug Abuse Research Using Existing Data**

The purpose of this Announcement is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. **Application Due Dates:** August 9, 2023; November 15, 2023; March 4, 2024; August 5, 2024; and November 15, 2024

[RFA-HL-22-010](#) (K01 Independent Clinical Trial Required)

[RFA-HL-22-011](#) (K01 Independent Clinical Trial Not Allowed)

#### **Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research**

This FOA invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations.

**Application Due Dates:** October 13, 2023 and February 13, 2024

[RFA-OD-22-023](#) – (K01 – Independent Clinical Trial Not Allowed)

[RFA-OD-22-024](#) – (K01 – Independent Clinical Trial Required)

#### **Mentored Research Scientist Career Development Award in Tobacco Regulatory Research**

The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research is to provide support and protected time for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. **Application Due Dates:** November 14, 2023; July 12, 2024; and March 12, 2025

[RFA-OD-22-025](#) – (K99/R00 – Independent Clinical Trial Not Allowed)

[RFA-OD-22-026](#) – (K99/R00 – Independent Clinical Trial Required)

**Pathway to Independence Award in Tobacco Regulatory Research**

The purpose of the Pathway to Independence Award in Tobacco Regulatory Research is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. **Application Due Dates:** November 14, 2023; July 12, 2024; and March 12, 2025

[RFA-DA-23-013](#) (R01 Clinical Trial Optional)

**NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes through Community-engaged Research**

This FOA seeks to fund innovative community partnered research by diverse teams that addresses community-driven priorities for reducing disparities in outcomes for racial and ethnic minority populations related to in substance use, addiction, and related health outcomes consequences, including HIV.

**Application Due Dates:** November 14, 2023 and November 14, 2024

[RFA-DA-23-061](#) (R01 Clinical Trial Optional)

[RFA-DA-23-062](#) (R34 Clinical Trial Optional)

**NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations**

The purpose of this FOA is to stimulate observational or intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities. **Application Due Dates:** November 14, 2023 and November 14, 2024

[RFA-DA-23-026](#) (DP1 Clinical Trial Optional)

**NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity**

This announcement invites applications supporting independent, early career or established scholars who self-identify as health equity, health disparities, or social determinants of health experts with the skills to make exceptionally creative contributions to the study of equity for underserved U.S. racial and/or ethnic minority groups that experience poorer outcomes related to substance use and substance use disorders. This award supports transformative, boundary-pushing applications that may be risky or at a stage too early to fare well in the traditional peer review process. **Application Due Dates:** November 14, 2023 and November 14, 2024

[RFA-DA-23-028](#) (R61/R33 Clinical Trial Optional)

**NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory**

This funding announcement invites exploratory mechanistic research seeking to parse the complex effects of structural racism and investigate its impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions. **Due Dates:** November 14, 2023 and November 14, 2024

[RFA-DA-23-053](#) (R61/R33 Clinical Trial Optional)

[RFA-DA-23-054](#) (R33 Clinical Trial Optional)

**HEAL Initiative: Translating Research to Practice to End the Overdose Crisis**

This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of evidence-based and promising treatments into routine use. **Due Dates:** November 15, 2023 and March 20, 2024

[RFA-OD-22-028](#) (R01 Clinical Trial Optional)

**The Intersection of Sex and Gender Influences on Health and Disease**

The purpose of this FOA is to invite applications on the influence and intersection of sex and gender in health and disease, including: (1) research applications that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the 2019-2023 [Trans-NIH Strategic Plan for Women's Health Research](#).

**Application Due Dates:** November 22, 2023 and November 22, 2024

[RFA-HL-23-004](#) (R35, Clinical Trial Optional)

**NHLBI Outstanding Investigator Award (OIA)**

This award provides long-term support and increased flexibility to experienced Program Directors/Principal Investigators who are currently PD/PIs on at least two NHLBI R01-equivalent awards. The OIA supports a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. **Application Due Date:** February 15, 2024

[RFA-HL-23-005](#) (R35, Clinical Trial Optional)

**NHLBI Emerging Investigator Award (EIA)**

The purpose of this award is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators who are currently PD/PIs on at least two NHLBI R01-equivalent awards. **Application Due Date:** February 15, 2024

[RFA-DA-22-040](#) (R01, Clinical Trial Optional)

**High Priority HIV and Substance Use Research**

This FOA supports high priority research at the intersection of HIV and substance use and invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment, and cure of HIV among people who use drugs (PWUD). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** February 16, 2024

[RFA-CA-22-045](#) (R35 Clinical Trial Optional)

**NCI Outstanding Investigator Award**

The Outstanding Investigator Award is based on the accomplishments of the applicant. It is meant to support the cancer research program of individual scientists of exceptional creativity, demonstrated outstanding research accomplishments, and seminal past contributions in cancer research. For this FOA, the research strategy is expected to evolve over the seven-year award period. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 8, 2024

[RFA-DA-23-008](#) (R61/R33, Clinical Trial Required)

**Stimulants and HIV: Addressing Contemporary and Recurring Epidemics**

The primary goal of this FOA is to support research to improve HIV prevention and care outcomes among people who use stimulants, encompassing a range of stimulant use (from episodic to persistent, methamphetamine and cocaine derivatives), including stimulant use co-occurring with the use of opioids and/or other drugs. **Application Due Dates:** Multiple Dates. **Expiration Date:** November 13, 2024

[RFA-DA-22-037](#) (R01, Clinical Trial Optional)

[RFA-DA-22-038](#) (R21, Clinical Trial Optional)

**Accelerating the Pace of Drug Abuse Research Using Existing Data**

This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. **Application Receipt Dates:** Multiple dates, see announcement. **Expiration Date:** November 16, 2024

[RFA-DA-23-021](#) (R43/R44, Clinical Trial Optional)

**Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)**

This FOA encourages SBIR grant applications directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders and/or stimulant use disorders. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** February 15, 2025

[RFA-NS-22-022](#) – (K99/R00 Independent Clinical Trial Not Allowed)

[RFA-NS-22-023](#) – (Independent Basis Experimental Studies with Humans Required)

**HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAID and SUD Research**

The purpose of this Announcement is to assist eligible postdoctoral researchers in research areas supported by the NIH HEAL Initiative®, with their transition to tenure-track or equivalent faculty positions and



establishment of independent research programs in Pain and SUD research. Applications appropriate for this FOA may propose biomedical research across the spectrum of Pain and SUD research areas. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** March 12, 2025

[RFA-NS-22-024](#) – (K99/R00 Independent Basic Experimental Studies with Humans Required)

[RFA-NS-22-025](#) – (K99/R00 Independent Clinical Trial Not Allowed)

#### **HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity**

The purpose of this FOA is to assist a cohort of new and talented independent investigators from diverse backgrounds (e.g. see [NOT-OD-20-031](#) Notice of NIH's Interest in Diversity) with their transition to tenure-track or equivalent faculty positions and establishment of independent research programs in Pain and SUD research. Applications appropriate for this FOA may propose biomedical research across the spectrum of Pain and SUD research areas. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** March 12, 2025

[RFA-ES-23-004](#) – (R21 Clinical Trial Not Allowed)

#### **Time-Sensitive Research Opportunities in Environmental Health Sciences**

This FOA is intended to support research in environmental health science in which an event has or will imminently occur that provides a limited window of opportunity to collect samples and data to support the assessment of exposures and human health impact. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** December 2, 2025

#### **NIH Funding Opportunities: Program Announcements Reviews in an Institute (PAR)**

[PAR-23-083](#) – (R61 Clinical Trial Optional)

#### **Pilot Studies for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline**

This FOA invites research grant applications that enable the collection of *pilot data* to support early-stage testing of promising pharmacological and non-pharmacological interventions that target deleterious cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD across the spectrum from pre-symptomatic to more severe stages of disease. The goal of these pilot data is to serve as preliminary data for applications to the early stage and late stage clinical trial [PAR-23-081](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 19, 2024

[PAR-23-081](#) – (R01 Clinical Trial Optional)

#### **Early and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Related Dementias and Age-Related Cognitive Decline**

This FOA invites research grant applications that enable the early- to late-stage testing of promising pharmacological and non-pharmacological interventions that target deleterious cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD across the spectrum from pre-symptomatic to more severe stages of disease. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2025

[PAR-23-116](#) – (P30 Clinical Trial Not Allowed)

#### **Centers for AIDS Research**

The purpose of this FOA is to invite applications for the Centers for AIDS Research (CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** August 5, 2025

[PAR-23-117](#) – (P30 Clinical Trial Not Allowed)

#### **Developmental Centers for AIDS Research**

The FOA is to invite applications for the Developmental Centers for AIDS Research (D-CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. D-CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. Additionally, D-CFARs provide support to assist investigators in the development of a competitive standard CFAR. **Application Due Dates:** Multiple Dates. **Expiration Date:** August 5, 2025

[PAR-23-125](#) – (DP2 Clinical Trial Optional)

**Avenir Award Program for Research on Substance Use Disorders and HIV**

This Avenir program looks towards the future by supporting early-stage investigators (ESI) proposing highly innovative studies at the nexus of substance use disorders (SUD) and HIV. This FOA aims to support broad spectrum of approaches spanning both basic and clinical research that have the potential to benefit substance using populations with or at risk for HIV. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** August 16, 2025

[PAR-23-055](#) – (R01 Clinical Trial Not Allowed)

[PAR-23-056](#) – (R21 Clinical Trial Not Allowed)

**Co-infection and Cancer**

This FOA is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Dates:** R01 – October 5, 2025; R21 – October 16, 2025

[PAR-23-072](#) – (R13 Clinical Trial Not Allowed)

**FDA Support for Conferences and Scientific Meetings**

The purpose of the FDA Scientific Conference Grant Program is to facilitate the provision of federal financial assistance in support of high-quality conferences and scientific meetings designed to research and investigate a topic clearly aligned with the FDA mission. *A Letter of Intent requesting advanced permission to submit a conference application is required and must be received via e-mail no later than eight (8) weeks prior to the selected application due date.* **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** October 11, 2025

[PAR-23-051](#) – (U01 Clinical Trial Not Allowed)

[PAR-23-052](#) – (UH2 Clinical Trial Not Allowed)

**Mechanistic links between diet, lipid metabolism, and tumor growth and progression**

The purpose of this funding opportunity announcement is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** October 24, 2025

[PAR-23-076](#) – P50 Clinical Trial Optional)

**NIDA Research Center of Excellence Grant Program**

This FOA is to provide support for research Centers that (1) conduct substance use and addiction research in any area of NIDA's mission, including the intersection of substance use/addiction and HIV, (2) foster outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to relevant research communities, educational organizations, the general public, and policy makers. **Application Due Dates:** Multiple dates; see announcement. **Expiration Date:** November 19, 2025

[PAR-23-053](#) – (R61/R33 – Clinical Trial Optional)

**Research Infrastructure Development for Interdisciplinary Aging Studies**

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. Applications should propose the development of research infrastructure to advance specific topics in aging science that require interdisciplinary partnerships or collaborations. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** December 3, 2025

[PAR-23-058](#) – (R03 Clinical Trial Optional)

**NCI Small Grants Program for cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus)**

This funding opportunity supports small research projects on cancer that can be carried out in a short period of time with limited resources. This grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development

of research methodology; and development of new research technology. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-034](#) – (R01 Clinical Trial Optional)

#### **NLM Research Grants in Biomedical Informatics and Data Science**

This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. **Due Dates:** Multiple Dates. **Expiration Date:** Jan. 8, 2026

[PAR-23-036](#) – (R21 Clinical Trial Not Allowed)

#### **Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders**

This FOA encourages applications that propose to conduct secondary analyses using existing human datasets in areas relevant to the National Heart, Lung, Blood Diseases and Sleep Disorders Institute (NHLBI) scientific mission. The FOA aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-057](#) – (R01 Clinical Trial Required)

#### **NIA Multi-site Clinical Trial Implementation Grant**

This FOA invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the [NIA website](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-064](#) – (P01 Clinical Trial Optional)

#### **NIDA Program Project Grant Applications**

NIDA seeks collaborative research by multi-disciplinary teams to address critical issues of neuroscience, genetics, behavior, prevention, treatment, epidemiology, etiology, medications development, health services, HIV/AIDS and co-occurring opportunistic infections (e.g., viral hepatitis C, tuberculosis, sexually transmitted infections) and associated consequences in people who use or misuse substances or have a substance use disorder, or other research areas relevant to substance use, misuse, or use disorders. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-112](#) – (R01 – Clinical Trial Optional)

#### **Addressing the Impact of Structural racism and Discrimination on Minority Health and Health Disparities**

This initiative will support intervention research that addresses structural racism and discrimination (SRD) in order to improve minority health or reduce health disparities. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-060](#) – (R34 Clinical Trial Optional)

#### **Formative and Pilot Intervention research to Optimize HIV Prevention and Care Continuum Outcomes**

[PAR-23-061](#) – (R21 Clinical Trial Optional)

[PAR-23-062](#) – (R01 Clinical Trial Optional)

#### **Innovations to Optimize HIV Prevention and Care Continuum Outcomes**

The NIMH invites applications for Research Project Grants that propose formative research, intervention development, and pilot-testing of interventions; formative implementation research to inform adaptation of evidence-based interventions; or development or selection of implementation strategies. Primary scientific areas of focus include the feasibility, acceptability, and safety of novel or adapted interventions that target HIV prevention or treatment, or implementation outcomes using implementation science approaches. Applications with preliminary data and/or those including longitudinal analysis, advanced modeling, or large-scale clinical trials or implementation science approaches should consider using the companion R01 mechanism, PAR-23-062. If proposing to conduct exploratory, novel studies that break new ground, extend previous discoveries in new directions or result in novel techniques, models, applications should consider the R21 mechanism (PAR-23-061). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 10, 2026

[PAR-23-077](#) – (RM1 – Clinical Trial Optional)

**Collaborative Program Grant for Multidisciplinary Teams**

This Announcement encourages Collaborative Program Grant applications from institutions/organizations that propose projects addressing complex and challenging biomedical problems within the mission of NIGMS. **Application Due Dates:** Multiple Dates, see announcement. **Expiration Date:** January 28, 2026

[PAR-23-037](#) – (U01 Clinical Trial Optional)

**Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities**

The purpose of this FOA is to invite applications for multisite clinical trials and large scale observational studies developed in conjunction with NICHD Networks that will be conducted using NICHD-supported Network infrastructure. The goal of this FOA is to operationalize the previously reported NICHD guiding principles for multisite clinical trials delineated in Notice [NOT-HD-19-034](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-111](#) – (R21 – Clinical Trial Optional)

**NIMHD Exploratory/Developmental Research Grant Program**

NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

**NIH Funding Opportunities: Program Announcements (PA)**

The following opportunities have standard due dates unless noted otherwise:

[PA-23-048](#)

**Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (T32)**

Expiration Date: May 8, 2026

[PA-23-080](#)

**Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grant (Parent T35)**

Expiration Date: May 8, 2026

[PA-23-115](#)

**AHRQ Small Research Project to Advance the Science of Primary Care (R03)**

Expiration Date: March 19, 2027

**Words to Live By**

"Laughter is an instant vacation."

– Milton Berle

For more information on RAS services, visit our website at [sphhp.buffalo.edu/ras](https://sphhp.buffalo.edu/ras)